BOSTON, Sept. 12, 2024 -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced positive Phase 2 end of study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and life-threatening ocular cancer. The results were presented at The Retina Society Annual Meeting, on Thursday, September 12, 2024, in Lisbon, Portugal.
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Sorriso Pharmaceuticals Completes Enrollment in Phase 1b Clinical Trial of Patients with Ulcerative Colitis
SALT LAKE CITY, UT, UNITED STATES, September 3, 2024 -- Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral antibodies for immune-mediated disease, today announced the completion of patient enrollment in its Phase 1b clinical trial evaluating the safety, tolerability, and preliminary efficacy of SOR102, a bispecific oral dual-acting biologic for the treatment of ulcerative colitis.
EarthOptics, Pattern Ag Merge to Digitize Soil Health for Climate and Agriculture
ARLINGTON, VA and EMERYVILLE, CA – August 28, 2024 – EarthOptics and Pattern Ag have merged, creating a category leader in soil digitization to power advanced crop management and climate sustainability. The newly combined soil intelligence company will operate under the name EarthOptics and be the authoritative source of soil insights and the leader in Predictive Agronomy. Its comprehensive data will enable farmers and advisors to know their soil's exact physical, chemical, and biological properties, helping them plan their most impactful input and management decisions to maximize profitability and sustainability goals. The combination pairs Pattern Ag’s cutting-edge lab-based analysis with proprietary field-based sensing technologies from EarthOptics to create a high-resolution digital twin of the soil, giving farmers insights into pests and pathogens, biofertility, nutrients, soil compaction, carbon levels, moisture, and more.
Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
Frederick, MD., Aug. 14, 2024 -- Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to VLX-1005, a small molecule 12-LOX inhibitor for the treatment of platelet-activating anti-platelet factor 4 (PF4) disorders. VLX-1005 previously secured ODD from the U.S. Food and Drug Administration for prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia (HIT) as well as FDA Fast Track Designation. This latest decision in Europe represents another regulatory achievement and builds on the successful development of VLX-1005 that has progressed through completed Phase 1 clinical studies, and into the ongoing Phase 2 trial ALATHEA (“A study of VLX-1005 to evaluate thrombocyte change in HEpArin-induced thrombocytopenia”).
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain
Mataró, Barcelona, Spain, 11 June, 2024 - Minoryx Therapeutics today announced that results from a compassionate use study of leriglitazone for treatment of progressive cerebral adrenoleukodystrophy (cALD) in adult male patients, published1 in the peer-reviewed journal Brain.
Aktis Oncology enters into Strategic Collaboration with Lilly
BOSTON, Mass. – May 21, 2024 — Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, today announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform. The collaboration draws on Aktis’ proprietary radiopharmaceutical platform together with Lilly’s expertise in oncology drug development and commercialization, with the goal of developing first- in-class and differentiated therapeutics for a range of solid tumors.
Enlaza Therapeutics Raises $100 Million through Its Series A Financing
LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further develop Enlaza’s proprietary covalent protein technologies and to support advancement of wholly owned pipeline programs to the clinic. The financing was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing investors: Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital. The financing also includes new investors: Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments.
Horizon Quantum Computing to Establish First-of-a-Kind Hardware Testbed
Singapore, 18 April 2024— Horizon Quantum Computing, a company building software development tools for quantum computers, today announced that it is establishing a first-of-a-kind testbed for integrating quantum computing hardware with its software stack, Triple Alpha. The testbed, which will be set up at Horizon’s Singapore headquarters, will have the capacity to host multiple quantum computers. By acquiring its own hardware, Horizon gains full control over both hardware and software stacks, allowing it to push the frontiers of quantum computing.
Us2.ai receives FDA clearance for Us2.v2,transforming cardiovascular ultrasound analysis
Singapore – April 5, 2024 – Us2.ai, a leading MedTech firm backed by prominent investors including IHH Healthcare, Heal Partners, Peak XV Partners (formerly Sequoia India) and EDBI, announces FDA clearance for Us2.v2, featuring 45 automated echo parameters, including strain analysis, marking a significant stride in medical innovation.
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease
SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a data with its combination adrenergic activator, CST-2032/CST-107, in patients with mild cognitive impairment (MCI) or mild dementia from either Alzheimer’s or Parkinson’s disease. The oral presentation will take place at AD/PD™ 2024: The International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held March 5-9, 2024, in Lisbon, Portugal.
